Literature DB >> 17207120

Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids.

Robert S Gable1.   

Abstract

AIM: To extend previous reviews by assessing the acute systemic toxicity and psychological hazards of a dimethyltryptamine and beta-carboline brew (ayahuasca/hoasca) used in religious ceremonies.
METHOD: A systematic literature search, supplemented by interviews with ceremony participants.
RESULTS: No laboratory animal models were located that tested the acute toxicity or the abuse potential of ayahuasca. Separate animal studies of the median lethal dose of dimethyltryptamine (DMT) and of several harmala alkaloids indicated that a lethal dose of these substances in humans is probably greater than 20 times the typical ceremonial dose. Adverse health effects may occur from casual use of ayahuasca, particularly when serotonergic substances are used in conjunction. DMT is capable of inducing aversive psychological reactions or transient psychotic episodes that resolve spontaneously in a few hours. There was no evidence that ayahuasca has substantial or persistent abuse potential. Long-term psychological benefits have been documented when ayahuasca is used in a well-established social context.
CONCLUSION: A decoction of DMT and harmala alkaloids used in religious ceremonies has a safety margin comparable to codeine, mescaline or methadone. The dependence potential of oral DMT and the risk of sustained psychological disturbance are minimal.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17207120     DOI: 10.1111/j.1360-0443.2006.01652.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  27 in total

1.  Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?

Authors:  Benjamin J Malcolm; Kelly C Lee
Journal:  Ment Health Clin       Date:  2018-03-23

2.  Forbidden therapies: Santo Daime, ayahuasca, and the prohibition of entheogens in Western society.

Authors:  Marc G Blainey
Journal:  J Relig Health       Date:  2015-02

Review 3.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

4.  Targeting sigma receptors: novel medication development for drug abuse and addiction.

Authors:  Rae R Matsumoto
Journal:  Expert Rev Clin Pharmacol       Date:  2009-07       Impact factor: 5.045

5.  An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders.

Authors:  Marika Renelli; Jenna Fletcher; Kenneth W Tupper; Natasha Files; Anya Loizaga-Velder; Adele Lafrance
Journal:  Eat Weight Disord       Date:  2018-11-24       Impact factor: 4.652

Review 6.  Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.

Authors:  Rafael G Dos Santos; José Carlos Bouso; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2017-02-23

7.  Abuse liability profile of three substituted tryptamines.

Authors:  Michael B Gatch; Michael J Forster; Aaron Janowsky; Amy J Eshleman
Journal:  J Pharmacol Exp Ther       Date:  2011-04-07       Impact factor: 4.030

Review 8.  Psychedelics in the treatment of unipolar and bipolar depression.

Authors:  Oliver G Bosch; Simon Halm; Erich Seifritz
Journal:  Int J Bipolar Disord       Date:  2022-07-05

9.  Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats.

Authors:  Michael B Gatch; Margaret A Rutledge; Theresa Carbonaro; Michael J Forster
Journal:  Psychopharmacology (Berl)       Date:  2009-03-14       Impact factor: 4.530

Review 10.  Serotonin toxicity of serotonergic psychedelics.

Authors:  Benjamin Malcolm; Kelan Thomas
Journal:  Psychopharmacology (Berl)       Date:  2021-07-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.